Back to top
more

Moderna (MRNA)

(Delayed Data from NSDQ)

$63.96 USD

63.96
24,069,834

+2.16 (3.50%)

Updated Jun 18, 2026 04:00 PM ET

After-Market: $64.03 +0.07 (0.11%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.00%
2Buy18.14%
3Hold10.18%
4Sell5.72%
5Strong Sell3.11%
S&P50011.49%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value C Growth F Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 38% (153 out of 247)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Stock Market News for Jan 7, 2026

by Zacks Equity Research

Wall Street closed sharply higher on Tuesday, led by materials, healthcare and chip stocks.

Zacks Equity Research

Why Investors Need to Take Advantage of These 2 Medical Stocks Now

by Zacks Equity Research

The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.

Zacks Equity Research

Moderna (MRNA) Soars 10.9%: Is Further Upside Left in the Stock?

by Zacks Equity Research

Moderna (MRNA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.

Zacks Equity Research

MRNA Stock Jumps on Global Submissions Seeking Nod for Flu Vaccine

by Zacks Equity Research

Moderna jumps after filings seeking approval for its mRNA-1010 flu vaccine across major markets, with plans to launch the shot for older adults next year.

Zacks Equity Research

Moderna (MRNA) Falls More Steeply Than Broader Market: What Investors Need to Know

by Zacks Equity Research

In the closing of the recent trading day, Moderna (MRNA) stood at $30.41, denoting a -2.38% move from the preceding trading day.

Zacks Equity Research

Moderna (MRNA) Stock Dips While Market Gains: Key Facts

by Zacks Equity Research

The latest trading day saw Moderna (MRNA) settling at $32.29, representing a -7.48% change from its previous close.

Zacks Equity Research

How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings

by Zacks Equity Research

Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.

Zacks Equity Research

MRNA to Get CEPI Funding for Phase III Study on Pandemic Influenza Jab

by Zacks Equity Research

Moderna secures up to $54.3 million from CEPI to fund a pivotal phase III study of its mRNA-based H5 pandemic flu vaccine candidate, mRNA-1018.

Zacks Equity Research

CHMP Backs EU Approval of MRNA's New COVID-19 Vaccine mNexspike

by Zacks Equity Research

CHMP backs EU approval of Moderna's next-generation mNexspike COVID-19 vaccine, with a final European Commission decision expected shortly.

Kinjel Shah headshot

MRK Stock Trading Above 200- & 50-Day SMA for 2 Months: Time to Buy?

by Kinjel Shah

Merck holds bullish momentum as pipeline advances and major deals offset vaccine weakness and Keytruda risks.